Skip to content
Adjuvance Technologies

Adjuvance Technologies

Empowering health.

  • About Us
  • Our Technology
  • Our Leadership
    • Management Team
    • Board of Directors
  • Investors & Media
  • Contact

Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

By jgardnerApril 1, 2016Publications
Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine

In a preclinical model, GSK scientists report a greater immune response to GSK Shingles vaccine (Hz/su) formulations that contain QS-21.

fochesato_AS01_HuVac

Post navigation

NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS

Recent Posts

  • ADJUVANCE TECHNOLOGIES ANNOUNCES NIH FUNDING FOR COVID-19 VACCINE RESEARCH
  • ADJUVANCE TECHNOLOGIES ANNOUNCES $20 MILLION SERIES A INVESTMENT FROM MORNINGSIDE VENTURE INVESTMENTS
  • Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
  • NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
  • Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
Copyright © All rights reserved. Theme Businessbiz by Sensational Theme